Other Species / Isoforms
  TAGLN2 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
R4-m1
____MANrGPAyGLs
0 3
TAGLN2 (human) ____MANrGPAyGLs R4-m1
TAGLN2 iso2 (human) PPIGMANRGPAYGLS R25
TAGLN2 (mouse) ____MANRGPsyGLS R4
TAGLN2 (rat) ____MANRGPsYGLS R4
A7
_MANrGPAyGLsREV
0 7
TAGLN2 (human) _MANrGPAyGLsREV A7
TAGLN2 iso2 (human) GMANRGPAYGLSREV A28
TAGLN2 (mouse) _MANRGPsyGLSREV S7-p
TAGLN2 (rat) _MANRGPsYGLSREV S7-p
Y8-p
MANrGPAyGLsREVQ
Upstream
0 341
Treatment
  • erlotinib
  • gefitinib
TAGLN2 (human) MANrGPAyGLsREVQ Y8-p
TAGLN2 iso2 (human) MANRGPAYGLSREVQ Y29
TAGLN2 (mouse) MANRGPsyGLSREVQ Y8-p
TAGLN2 (rat) MANRGPsYGLSREVQ Y8
S11-p
rGPAyGLsREVQQkI
Upstream
0 9
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • calyculin_A
  • phorbol_ester
TAGLN2 (human) rGPAyGLsREVQQkI S11-p
TAGLN2 iso2 (human) RGPAYGLSREVQQKI S32
TAGLN2 (mouse) RGPsyGLSREVQQKI S11
TAGLN2 (rat) RGPsYGLSREVQQkI S11
K17-ac
LsREVQQkIEkQYDA
Upstream
0 4
Treatment
  • vorinostat
TAGLN2 (human) LsREVQQkIEkQYDA K17-ac
TAGLN2 iso2 (human) LSREVQQKIEKQYDA K38
TAGLN2 (mouse) LSREVQQKIEkQYDA K17
TAGLN2 (rat) LSREVQQkIEKQYDP K17-ac
K17-ub
LsREVQQkIEkQYDA
0 3
TAGLN2 (human) LsREVQQkIEkQYDA K17-ub
TAGLN2 iso2 (human) LSREVQQKIEKQYDA K38
TAGLN2 (mouse) LSREVQQKIEkQYDA K17
TAGLN2 (rat) LSREVQQKIEKQYDP K17
K20-ac
EVQQkIEkQYDADLE
Upstream
0 5
Treatment
  • vorinostat
TAGLN2 (human) EVQQkIEkQYDADLE K20-ac
TAGLN2 iso2 (human) EVQQKIEKQYDADLE K41
TAGLN2 (mouse) EVQQKIEkQYDADLE K20-ac
TAGLN2 (rat) EVQQkIEKQYDPDLE K20
K20-ub
EVQQkIEkQYDADLE
0 7
TAGLN2 (human) EVQQkIEkQYDADLE K20-ub
TAGLN2 iso2 (human) EVQQKIEKQYDADLE K41
TAGLN2 (mouse) EVQQKIEKQYDADLE K20
TAGLN2 (rat) EVQQkIEKQYDPDLE K20
K40-ub
WITTQCRkDVGRPQP
0 4
TAGLN2 (human) WITTQCRkDVGRPQP K40-ub
TAGLN2 iso2 (human) WITTQCRKDVGRPQP K61
TAGLN2 (mouse) WITTQCREDVGQPQP E40
TAGLN2 (rat) WITTQCRKGVSQPQP K40
K57-sm
ENFQNWLkDGtVLCE
0 1
TAGLN2 (human) ENFQNWLkDGtVLCE K57-sm
TAGLN2 iso2 (human) ENFQNWLKDGTVLCE K78
TAGLN2 (mouse) ENFQKWLKDGTVLCk K57
TAGLN2 (rat) ENFQNWLKDGTVLCE K57
T60-p
QNWLkDGtVLCELIN
0 2
TAGLN2 (human) QNWLkDGtVLCELIN T60-p
TAGLN2 iso2 (human) QNWLKDGTVLCELIN T81
TAGLN2 (mouse) QKWLKDGTVLCkLIN T60
TAGLN2 (rat) QNWLKDGTVLCELIN T60
E64
kDGtVLCELINALYP
0 3
TAGLN2 (human) kDGtVLCELINALYP E64
TAGLN2 iso2 (human) KDGTVLCELINALYP E85
TAGLN2 (mouse) KDGTVLCkLINSLYP K64-ub
TAGLN2 (rat) KDGTVLCELINSLYP E64
K78-ac
PEGQAPVkkIQAstM
0 1
TAGLN2 (human) PEGQAPVkkIQAstM K78-ac
TAGLN2 iso2 (human) PEGQAPVKKIQASTM K99
TAGLN2 (mouse) PEGQAPVKkIQASSM K78
TAGLN2 (rat) PEGQAPVKKIQASTM K78
K78-ub
PEGQAPVkkIQAstM
0 12
TAGLN2 (human) PEGQAPVkkIQAstM K78-ub
TAGLN2 iso2 (human) PEGQAPVKKIQASTM K99
TAGLN2 (mouse) PEGQAPVKkIQASSM K78
TAGLN2 (rat) PEGQAPVKKIQASTM K78
K78-sc
PEGQAPVkkIQAstM
0 1
TAGLN2 (human) PEGQAPVkkIQAstM K78-sc
TAGLN2 iso2 (human) PEGQAPVKKIQASTM K99
TAGLN2 (mouse) PEGQAPVKkIQASSM K78
TAGLN2 (rat) PEGQAPVKKIQASTM K78
K79-ac
EGQAPVkkIQAstMA
0 1
TAGLN2 (human) EGQAPVkkIQAstMA K79-ac
TAGLN2 iso2 (human) EGQAPVKKIQASTMA K100
TAGLN2 (mouse) EGQAPVKKIQASSMA K79
TAGLN2 (rat) EGQAPVKKIQASTMA K79
K79-ub
EGQAPVkkIQAstMA
0 12
TAGLN2 (human) EGQAPVkkIQAstMA K79-ub
TAGLN2 iso2 (human) EGQAPVKKIQASTMA K100
TAGLN2 (mouse) EGQAPVKkIQASSMA K79-ub
TAGLN2 (rat) EGQAPVKKIQASTMA K79
K79-sm
EGQAPVkkIQAstMA
0 1
TAGLN2 (human) EGQAPVkkIQAstMA K79-sm
TAGLN2 iso2 (human) EGQAPVKKIQASTMA K100
TAGLN2 (mouse) EGQAPVKKIQASSMA K79
TAGLN2 (rat) EGQAPVKKIQASTMA K79
S83-p
PVkkIQAstMAFkQM
Upstream
Downstream
1 2
Effects on Modified Protein
  • molecular association, regulation
Effects on Biological Processes:
  • carcinogenesis, induced
  • cell motility, induced
  • cytoskeletal reorganization
Putative in vivo kinases:
  • CDK14 (human)
Treatment
  • siRNA
TAGLN2 (human) PVkkIQAstMAFkQM S83-p
TAGLN2 iso2 (human) PVKKIQASTMAFKQM S104
TAGLN2 (mouse) PVKkIQASSMAFKQM S83
TAGLN2 (rat) PVKKIQASTMAFKQM S83
T84-p
VkkIQAstMAFkQME
Upstream
0 1
Treatment
  • calyculin_A
TAGLN2 (human) VkkIQAstMAFkQME T84-p
TAGLN2 iso2 (human) VKKIQASTMAFKQME T105
TAGLN2 (mouse) VKkIQASSMAFKQME S84
TAGLN2 (rat) VKKIQASTMAFKQME T84
K88-ac
QAstMAFkQMEQIsQ
0 8
TAGLN2 (human) QAstMAFkQMEQIsQ K88-ac
TAGLN2 iso2 (human) QASTMAFKQMEQISQ K109
TAGLN2 (mouse) QASSMAFKQMEQISQ K88
TAGLN2 (rat) QASTMAFKQMEQISQ K88
K88-ub
QAstMAFkQMEQIsQ
0 4
TAGLN2 (human) QAstMAFkQMEQIsQ K88-ub
TAGLN2 iso2 (human) QASTMAFKQMEQISQ K109
TAGLN2 (mouse) QASSMAFKQMEQISQ K88
TAGLN2 (rat) QASTMAFKQMEQISQ K88
S94-p
FkQMEQIsQFLQAAE
0 1
TAGLN2 (human) FkQMEQIsQFLQAAE S94-p
TAGLN2 iso2 (human) FKQMEQISQFLQAAE S115
TAGLN2 (mouse) FKQMEQISQFLQAAE S94
TAGLN2 (rat) FKQMEQISQFLQAAE S94
T128-p
NMACVQRtLMNLGGL
0 2
TAGLN2 (human) NMACVQRtLMNLGGL T128-p
TAGLN2 iso2 (human) NMACVQRTLMNLGGL T149
TAGLN2 (mouse) NMACVQRTLMNLGGL T128
TAGLN2 (rat) NMACVQRTLMNLGGL T128
R139-m2
LGGLAVArDDGLFsG
0 1
TAGLN2 (human) LGGLAVArDDGLFsG R139-m2
TAGLN2 iso2 (human) LGGLAVARDDGLFSG R160
TAGLN2 (mouse) LGGLAVARDDGLFSG R139
TAGLN2 (rat) LGGLAVARDDGLFSG R139
S145-p
ArDDGLFsGDPNWFP
Upstream
Downstream
1 3
Effects on Modified Protein
  • protein stabilization
Effects on Biological Processes:
  • carcinogenesis, induced
  • cell growth, induced
Kinase, in vitro:
  • ERK2 (human)
Putative in vivo kinases:
  • ERK2 (human)
Regulatory protein:
  • KRas (human)
Treatment
  • LY294002
  • U0126
TAGLN2 (human) ArDDGLFsGDPNWFP S145-p
TAGLN2 iso2 (human) ARDDGLFSGDPNWFP S166
TAGLN2 (mouse) ARDDGLFSGDPNWFP S145
TAGLN2 (rat) ARDDGLFSGDPNWFP S145
K153-ac
GDPNWFPkkSkENPR
0 4
TAGLN2 (human) GDPNWFPkkSkENPR K153-ac
TAGLN2 iso2 (human) GDPNWFPKKSKENPR K174
TAGLN2 (mouse) GDPNWFPkKSKENPR K153-ac
TAGLN2 (rat) GDPNWFPKKSKENPR K153
K153-ub
GDPNWFPkkSkENPR
0 4
TAGLN2 (human) GDPNWFPkkSkENPR K153-ub
TAGLN2 iso2 (human) GDPNWFPKKSKENPR K174
TAGLN2 (mouse) GDPNWFPKKSKENPR K153
TAGLN2 (rat) GDPNWFPKKSKENPR K153
K153-sc
GDPNWFPkkSkENPR
0 1
TAGLN2 (human) GDPNWFPkkSkENPR K153-sc
TAGLN2 iso2 (human) GDPNWFPKKSKENPR K174
TAGLN2 (mouse) GDPNWFPkKSKENPR K153-sc
TAGLN2 (rat) GDPNWFPKKSKENPR K153
K154-ub
DPNWFPkkSkENPRN
0 2
TAGLN2 (human) DPNWFPkkSkENPRN K154-ub
TAGLN2 iso2 (human) DPNWFPKKSKENPRN K175
TAGLN2 (mouse) DPNWFPkKSKENPRN K154
TAGLN2 (rat) DPNWFPKKSKENPRN K154
K156-ub
NWFPkkSkENPRNFs
0 1
TAGLN2 (human) NWFPkkSkENPRNFs K156-ub
TAGLN2 iso2 (human) NWFPKKSKENPRNFS K177
TAGLN2 (mouse) NWFPkKSKENPRNFs K156
TAGLN2 (rat) NWFPKKSKENPRNFs K156
S163-p
kENPRNFsDNQLQEG
Upstream
Downstream
1 96
Effects on Modified Protein
  • molecular association, regulation
Effects on Biological Processes:
  • carcinogenesis, induced
  • cell motility, induced
  • cytoskeletal reorganization
Putative in vivo kinases:
  • CDK14 (human)
  • PKACA (human)
Treatment
  • angiotensin_2
  • anti-CD3
  • calyculin_A
  • colforsin
  • dasatinib
  • EGF
  • ionizing_radiation
  • nocodazole
  • siRNA
TAGLN2 (human) kENPRNFsDNQLQEG S163-p
TAGLN2 iso2 (human) KENPRNFSDNQLQEG S184
TAGLN2 (mouse) KENPRNFsDNQLQEG S163-p
TAGLN2 (rat) KENPRNFsDNQLQEG S163-p
K171-ac
DNQLQEGkNVIGLQM
0 5
TAGLN2 (human) DNQLQEGkNVIGLQM K171-ac
TAGLN2 iso2 (human) DNQLQEGKNVIGLQM K192
TAGLN2 (mouse) DNQLQEGKNVIGLQM K171
TAGLN2 (rat) DNQLQEGkNVIGLQM K171-ac
K171-ub
DNQLQEGkNVIGLQM
0 45
TAGLN2 (human) DNQLQEGkNVIGLQM K171-ub
TAGLN2 iso2 (human) DNQLQEGKNVIGLQM K192
TAGLN2 (mouse) DNQLQEGkNVIGLQM K171-ub
TAGLN2 (rat) DNQLQEGKNVIGLQM K171
K171-sm
DNQLQEGkNVIGLQM
0 1
TAGLN2 (human) DNQLQEGkNVIGLQM K171-sm
TAGLN2 iso2 (human) DNQLQEGKNVIGLQM K192
TAGLN2 (mouse) DNQLQEGKNVIGLQM K171
TAGLN2 (rat) DNQLQEGKNVIGLQM K171
T180-p
VIGLQMGtNrGAsQA
Upstream
0 26
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • calyculin_A
  • phorbol_ester
TAGLN2 (human) VIGLQMGtNrGAsQA T180-p
TAGLN2 iso2 (human) VIGLQMGTNRGASQA T201
TAGLN2 (mouse) VIGLQMGtNrGAsQA T180-p
TAGLN2 (rat) VIGLQMGTNrGASQA T180
R182-m1
GLQMGtNrGAsQAGM
0 28
TAGLN2 (human) GLQMGtNrGAsQAGM R182-m1
TAGLN2 iso2 (human) GLQMGTNRGASQAGM R203
TAGLN2 (mouse) GLQMGtNrGAsQAGM R182-m1
TAGLN2 (rat) GLQMGTNrGASQAGM R182-m1
S185-p
MGtNrGAsQAGMtGy
Upstream
0 54
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • anti-CD3
  • calyculin_A
  • phorbol_ester
TAGLN2 (human) MGtNrGAsQAGMtGy S185-p
TAGLN2 iso2 (human) MGTNRGASQAGMTGY S206
TAGLN2 (mouse) MGtNrGAsQAGMTGy S185-p
TAGLN2 (rat) MGTNrGASQAGMTGY S185
T190-p
GAsQAGMtGyGMPrQ
0 23
TAGLN2 (human) GAsQAGMtGyGMPrQ T190-p
TAGLN2 iso2 (human) GASQAGMTGYGMPRQ T211
TAGLN2 (mouse) GAsQAGMTGyGMPrQ T190
TAGLN2 (rat) GASQAGMTGYGMPrQ T190
Y192-p
sQAGMtGyGMPrQIL
Upstream
0 1172
Treatment
  • ephrin_B1
  • ephrin_B2
  • erlotinib
  • gefitinib
  • Su11274
  • U0126
TAGLN2 (human) sQAGMtGyGMPrQIL Y192-p
TAGLN2 iso2 (human) SQAGMTGYGMPRQIL Y213
TAGLN2 (mouse) sQAGMTGyGMPrQIL Y192-p
TAGLN2 (rat) SQAGMTGYGMPrQIL Y192
R196-m1
MtGyGMPrQIL____
0 38
TAGLN2 (human) MtGyGMPrQIL____ R196-m1
TAGLN2 iso2 (human) MTGYGMPRQIL____ R217
TAGLN2 (mouse) MTGyGMPrQIL____ R196-m1
TAGLN2 (rat) MTGYGMPrQIL____ R196-m1
R196
MtGyGMPRQIL____
0 4
TAGLN2 (human) MtGyGMPRQIL____ R196
TAGLN2 iso2 (human) MTGYGMPRQIL____ R217
TAGLN2 (mouse) MTGyGMPrQIL____ R196-m2
TAGLN2 (rat) MTGYGMPRQIL____ R196